Highlights

  • Botanix reported Q4 FY26 net Revenue of $10.1 million, up 45% from the prior quarter.
  • Sofdra prescriptions increased 25% quarter-on-quarter to 33,358 units.
  • The company improved gross-to-net Yield to 22% from 18%.
  • Botanix ended Q4 FY26 with $36.6 million in cash.

Botanix Pharmaceuticals (ASX:BOT) is a commercial-stage dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. The company is working to expand commercial adoption of Sofdra following its transition from clinical development into product sales.

At the time of writing on 14 August 2026, Botanix Pharmaceuticals (ASX:BOT) was trading at AUD 0.022, unchanged on the day.

The company’s latest quarterly update highlighted growth in prescriptions, revenue expansion and efforts to improve operating efficiency as the Sofdra launch progresses.

What Just Happened?

On 27 July 2026, Botanix released its quarterly results for the three months ended 30 June 2026. The company reported Sofdra prescription shipments of 33,358 units during the quarter, increasing from 26,684 units in the March quarter.

Gross sales increased to $46.7 million from $38.0 million, while net revenue increased to $10.1 million from $6.9 million.

The company also reported improvement in gross-to-net yield, which increased to 22% from 18%. Gross-to-net yield reflects the amount of recognised revenue retained after rebates and discounts.

Operating cash outflow reduced to $10.6 million, representing a 54% improvement compared with the March quarter’s $23.3 million outflow. Botanix ended the period with $36.6 million in cash, supported by a $30.1 million Capital raise completed during the quarter.

The company also reduced its United States sales force by 11 representatives from 31 July, with management expecting approximately 12% lower operating costs.

Why It Matters

For Botanix, the key challenge following regulatory approval has been converting Sofdra into a commercially sustainable product. The latest quarterly results provide further information on prescription growth, revenue conversion and cost management.

The increase in gross-to-net yield is relevant because it indicates a higher proportion of gross sales converting into recognised revenue after payer adjustments and discounts.

The reduction in operating cash outflow also provides additional visibility on the company’s ability to manage commercial expansion while controlling expenditure.

However, the company remains dependent on Sofdra performance, and maintaining prescription growth while improving commercial efficiency will be important for future financial outcomes.

The Bigger Picture

Botanix Pharmaceuticals is a dermatology-focused company headquartered in Phoenix, Arizona, with its primary listing on the ASX. Its main product, Sofdra, contains sofpironium bromide and is approved by the United States Food and Drug Administration for the treatment of primary axillary hyperhidrosis.

The product is designed for adults and children aged nine years and older with excessive underarm sweating. Prior to Sofdra, treatment Options included over-the-counter products, off-label therapies and procedures.

The company’s strategy is centred on commercialising Sofdra while protecting its intellectual property position. In July 2026, Botanix received a Notice of Allowance from the United States Patent and Trademark Office covering the crystalline form of sofpironium bromide and its Manufacturing method.

The company stated that its patent protection extends to 2040, supporting the commercialisation period for the product.

What Could Drive the Shares Next?

The continued performance of Sofdra prescriptions and gross-to-net yield remain key factors for Botanix. Investors will monitor whether the improvement achieved during Q4 FY26 continues into FY27.

Further reductions in operating cash outflow and progress toward improved cash efficiency will also remain important.

Additional developments around patent protection, including formal issuance of allowed patents and international intellectual property progress, may influence expectations.

The company’s ability to maintain prescription growth with a smaller sales team will also be monitored as part of the broader commercial strategy.

Risks Investors Should Watch

Botanix faces risks associated with product concentration, commercial execution and market adoption. The company relies heavily on Sofdra as its primary commercial asset, meaning slower prescription growth or weaker market uptake could significantly affect performance. United States payer dynamics may affect revenue conversion through changes in rebates and discounts. Reducing the sales force may create execution challenges if customer Acquisition slows. The company remains pre-profit and may require additional funding if cash generation does not improve. Additional risks include competition, intellectual property challenges and Volatility associated with smaller biotechnology companies.

Bottom Line

Botanix Pharmaceuticals (ASX:BOT) is progressing the commercial rollout of Sofdra, reporting higher prescriptions, increased net revenue and improved Operating Cash Flow performance during Q4 FY26.

The company’s latest results provide further insight into the commercial adoption of its dermatology product and efforts to improve launch efficiency. However, Botanix remains dependent on Sofdra execution and continued prescription growth.

Future performance will depend on maintaining revenue expansion, improving cash generation, protecting intellectual property and successfully establishing Sofdra within the dermatology market.